Navigation Links
Moffitt Cancer Center Receives Prestigious SPORE Grant Worth More Than $10 Million
Date:9/2/2008

TAMPA, Fla., Sept. 2 /PRNewswire/ -- The National Cancer Institute (NCI) has awarded Dr. Gerold Bepler, program leader for thoracic oncology at Moffitt Cancer Center ( http://www.moffitt.org ), and his team a Specialized Programs of Research Excellence (SPORE) grant in lung cancer. The grant totals $10,475,090 over five years. This is Moffitt's first SPORE grant, which puts them in the company of other leading cancer centers like University of Texas M. D. Anderson Cancer Center, Johns Hopkins Hospital and Mayo Clinic.

"This grant acknowledges the continued translational work done by the entire lung team at Moffitt, which has been recognized nationally and internationally," Bepler said. "Our entire team is extremely honored to be recognized by a panel of national lung cancer experts at the level of the NCI. It will provide us the opportunity to continue and significantly enhance our efforts to contribute to the prevention and cure of lung cancer."

Lung cancer is the leading cause of cancer death for men and women. Florida is second behind California in the number of new lung cancer cases per year.
Moffitt will conduct four research projects with various team members.

1. E2Fs impact on therapeutic efficacy

-- Douglas Cress, Ph.D., Jiandong Chen, Ph.D., Bepler

2. -- Antitumor mechanism of src inhibitors

-- Eric Haura, M.D., Jin Cheng, M.D., Ph.D., and Jack Pledger, Ph.D.

3. Chemoprevention with enzasataurin

-- Bepler and Mark Alexandrow, Ph.D.

4. P53-based vaccine for small cell lung cancer

-- Dmitry Gabrilovich, M.D., Ph.D. and Scott Antonia, M.D., Ph.D.

For more information on the Lung Cancer SPOREs program, visit the NCI website: http://spores.nci.nih.gov/current/lung/lung.html

About H. Lee Moffitt Cancer Center & Research Institute

Located in Tampa, Florida, Moffitt Cancer Center is the only Florida-based cancer center with the NCI designation as a Comprehensive Cancer Center for its excellence in research and contributions to clinical trials, prevention and cancer control. Moffitt currently has 15 affiliates in Florida, one in Georgia and two in Puerto Rico. Additionally, Moffitt is a member of the National Comprehensive Cancer Network, a prestigious alliance of the country's leading cancer centers, and is listed in U.S. News & World Report as one of "America's Best Hospitals" for cancer. Moffitt's sole mission is to contribute to the prevention and cure of cancer.


'/>"/>
SOURCE H. Lee Moffitt Cancer Center & Research Institute
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Moffitt Cancer Center Joins National Campaign To Implore Americans To Donate $1 To Accelerate Cancer Research
2. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
3. Johns Hopkins to add Elekta Synergy S(R) to Cancer Treatment Lineup
4. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
5. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
6. GlaxoSmithKline Recognizes University of Michigans Dr. Daniel F. Hayes as the First Recipient of the Gianni Bonadonna Breast Cancer Award
7. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
8. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
9. Novel Technology Breaks Through Cancer Pain
10. ONCOSCIENCE AG, THE EUROPEAN PARTNER OF YM BIOSCIENCES, ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE III BRAIN CANCER TRIAL OF NIMOTUZUMAB
11. Pharmion and MethylGene Announce Collaboration to Develop Sirtuin Inhibitors as Anti-Cancer Agents
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... ... 2016 , ... Researchers at the Universita Politecnica delle Marche in Ancona combed ... pleural mesothelioma. Their findings are the subject of a new article on the Surviving ... signposts in the blood, lung fluid or tissue of mesothelioma patients that can help ...
(Date:6/23/2016)... CAMBRIDGE, Mass. , June 23, 2016 /PRNewswire/ ... the development of novel compounds designed to target ... compound, napabucasin, has been granted Orphan Drug Designation ... in the treatment of gastric cancer, including gastroesophageal ... cancer stemness inhibitor designed to inhibit cancer stemness ...
(Date:6/23/2016)... Houston Methodist Willowbrook Hospital has signed ... to serve as their official health care provider. ... will provide sponsorship support, athletic training services, and ... volunteers, athletes and families. "We are ... and to bring Houston Methodist quality services and ...
(Date:6/23/2016)... , June, 23, 2016  The Biodesign Challenge ... envision new ways to harness living systems and biotechnology, ... Art (MoMA) in New York City ... 130 participating students, showcased projects at MoMA,s Celeste Bartos ... Paola Antonelli , MoMA,s senior curator of architecture and ...
Breaking Biology Technology:
(Date:5/3/2016)... 2016  Neurotechnology, a provider of high-precision biometric ... Biometric Identification System (ABIS) , a complete system ... ABIS can process multiple complex biometric transactions with ... fingerprint, face or iris biometrics. It leverages the ... MegaMatcher Accelerator , which have been used ...
(Date:4/26/2016)... and LONDON , April ... part of EdgeVerve Systems, a product subsidiary of ... today announced a partnership to integrate the Onegini ...      (Logo: http://photos.prnewswire.com/prnh/20151104/283829LOGO ) ... their customers enhanced security to access and transact ...
(Date:4/15/2016)... CHICAGO , April 15, 2016  A ... companies make more accurate underwriting decisions in a ... offering timely, competitively priced and high-value life insurance ... health screenings. With Force Diagnostics, rapid ... and lifestyle data readings (blood pressure, weight, pulse, ...
Breaking Biology News(10 mins):